 Morphic Holding, Inc. Morphic, a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of 15.00 per share. Jefferies LLC, Cowen and Company, LLC, BMO Capital Markets Corp. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on June 26, 2019. 